Niagen Bioscience, Inc. NAGE
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -8.71% | -5.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -8.71% | -5.37% | |||
| Cost of Revenue | -3.67% | -8.93% | |||
| Gross Profit | -11.44% | -3.31% | |||
| SG&A Expenses | -1.20% | 1.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.05% | -2.72% | |||
| Operating Income | -326.71% | -55.58% | |||
| Income Before Tax | -209.73% | -84.13% | |||
| Income Tax Expenses | -- | -74.58% | |||
| Earnings from Continuing Operations | -221.81% | -84.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -221.81% | -84.76% | |||
| EBIT | -326.71% | -55.58% | |||
| EBITDA | -230.88% | -46.92% | |||
| EPS Basic | -222.31% | -84.70% | |||
| Normalized Basic EPS | -210.71% | -45.10% | |||
| EPS Diluted | -248.00% | -85.71% | |||
| Normalized Diluted EPS | -214.81% | -43.75% | |||
| Average Basic Shares Outstanding | -0.22% | -0.74% | |||
| Average Diluted Shares Outstanding | -4.07% | -2.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||